Edith Huland
-
Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study
Edith Huland, A. Burger, J. Fleischer, P. Fornara, E. Hatzmann, A. Heidenreich, H. Heinzer, H. Heynemann, L. Hoffmann, R. Hofmann, H. Huland, I. Kämpfer, M. Kindler, H. Kirchner, G. Mehlhorn, T. H. Moniak, U. Rebmann, J. Roigas, T. H. Schneider, D. Schnorr, H.-J. Schmitz, R. Wenisch, Z. Varga, J. Vinke
2003, Vol. 49, Issue 5, pp. 183-190 -
Interleukin-2 and Cancer - Physiological and Pharmacological Uses
Edith Huland
2001, Vol. 47, Issue 4, pp. 111-112 -
A Comparison of Systemic Versus Inhaled Recombinant IL-2 Administration for the Treatment of Metastatic Renal Cell Carcinoma
Edith Huland, H. Heinzer, H. Huland
2000, Vol. 46, Issue 6, pp. 241-250
